The FDA has received 30 reports of cancer in children under the age of 18 who had been treated for JIA with anti-TNF drugs along with other medications, such as methotrexate, or similar immunosuppressant drugs. [...]
|
|||||||
|
A report published today by the Centers for Disease Control and Prevention estimates that 300,000 children in the U.S. suffer from some from of arthritis. Included in that estimate are some 50,000 to 100,000 that suffer from juvenile rheumatoid arthritis, a disease that can lead to permanent joint damage. This report, published in the [...] Swedish researchers have been investigating the link between serious infections during the first year of life and the risk of rheumatoid arthritis (RA). There have been previous studies that have indicated that infections can cause autoimmune diseases in adulthood. The current study seems to show that an infection in infants interferes with the normal maturation of the immune system. [...] Many women who suffered with the symptoms of rheumatoid arthritis found that they got relief from the pain during pregnancy. It was not understood what caused this phenomenon but researchers have delved into this question and it appears they have discovered a possible mechanism that provides relief. The answer may lie in the fetus’ [...] The FDA ordered that the class of drugs known as TNF blockers carry a warning on the packaging that their use carries the risk of developing a potentially deadly fungal disease called histoplasmosis. [...] Etanercept, marketed under the name Enbrel, is a drug that belongs to the class of drugs known as tumor necrosis factor (TNF)-alpha blocker. It is used primarily to treat rheumatoid arthritis, but has also been approved for use in treating polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. On May 1st, the [...] Treatments prescribed for treatment of rheumatoid arthritis in adults may not be well tolerated in children. Studies presented last month at the American College of Rheumatology (ACR) suggest that some of these drugs are appropriate for treating juvenile rheumatoid arthritis (JRA). Three studies were included in the report which included data on adalimumab (Humira), [...] |
  
|
||||||
|
Copyright © 2012 Current Arthritis News and Research - All Rights Reserved
|
|||||||
